Navigation Links
Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
Date:8/29/2007

BEDFORD, Mass., Aug. 29 /PRNewswire-FirstCall/ -- Insulet Corporation (Nasdaq: PODD), the manufacturer and marketer of the OmniPod(R) Insulin Management System, today announced that Duane DeSisto, Chief Executive Officer, will participate in the Thomas Weisel Partners Healthcare Conference. Mr. DeSisto is scheduled to present an overview of the Company at 3:50 p.m. Eastern Time on September 6, 2007 at The Four Seasons Hotel in Boston, MA.

During the conference presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of the presentation during the event, please visit: http://investors.insulet.com. A replay of the webcast will be available for 30 days.

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.

Contact:

Stephanie Marks for Insulet Corporation

ir@insulet.com

877-PODD-IR1 (877-763-3471)


'/>"/>
SOURCE Insulet Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. Wisconsin firms to present at Cleantech venture capital event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... The Academy of Model Aeronautics ... and 29, 2017, to promote AMA’s programs, member services, and the model aviation ... including but not limited to model aviation and other RC activities. , Thousands ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... includes executive, engineering and manufacturing functions to The LaunchPort™ Accelerator at the City ... a full range of manufacturing and business services to its Residents. , ...
(Date:9/21/2017)... ... September 21, 2017 , ... The 3rd World Congress on ... latest knowledge on these products, which are increasingly used in crop production around ... Biostimulants on Plant Nutrition, Abiotic Stresses, Plant Growth and Development, as well as ...
(Date:9/21/2017)... ... September 21, 2017 , ... Executives and ... world’s most progressive pharma and biotech organizations to do more clinical trials will ... biotech events in Q4. , DrugDev will demonstrate DrugDev Spark™, the world’s first ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):